Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2019.
- 10 Feb 2017 Planned number of patients changed from 28 to 58.